CALL FOR ABSTRACTS

AACR-NCI-EORTC INTERNATIONAL CONFERENCE

MOLECULAR TARGETS AND CANCER THERAPEUTICS

DISCOVERY, BIOLOGY, AND CLINICAL APPLICATIONS

THE PREMIER INTERNATIONAL MEETING FEATURING NOVEL CANCER THERAPEUTICS

October 26-30, 2017
Pennsylvania Convention Center | Philadelphia, PA

Abstract Submission Deadline: Sunday, July 23 • Late-Breaking Abstract Submission Deadline: Thursday, September 7
Early Registration Deadline: Tuesday, August 22

Continuing Medical Education Activity-
AMA PRA Category 1 Credits™ available

www.AACR.org
TABLE OF CONTENTS

Organizing and Scientific Committees.......................................................... 2
Program Schedule......................................................................................... 4
Abstract Submission Categories and Guidelines............................................ 8
Late-Breaking Abstract Submission Guidelines............................................. 10
Accommodations and Travel......................................................................... 11
Continuing Medical Education...................................................................... 13
Financial Support for Attendance................................................................. 14
Registration.................................................................................................. 15
General Information....................................................................................... 16
Press............................................................................................................... 18
Support Opportunities.................................................................................... 20
Exhibit Information....................................................................................... 21
Webcasts of Sessions..................................................................................... 22
Registration Form.......................................................................................... 23

ABOUT THE COVER
ABOUT THE CONFERENCE ORGANIZERS

Founded in 1907, the American Association for Cancer Research (AACR) is the world’s first and largest scientific organization in the world focused on every aspect of high-quality, innovative cancer research. Its reputation for scientific breadth and excellence attracts the premier researchers in the field. The programs and services of the AACR foster the exchange of knowledge and new ideas among scientists dedicated to cancer research, provide training opportunities for the next generation of cancer researchers, and increase public understanding of cancer.

The mission of the AACR is to prevent and cure cancer through research, education, communication, and collaboration. Through its programs and services, the AACR fosters research in cancer and related biomedical science; accelerates the dissemination of new research findings among scientists and others dedicated to the conquest of cancer; promotes science education and training; and advances the understanding of cancer etiology, prevention, diagnosis, and treatment throughout the world.

The National Cancer Institute (NCI), founded in 1937, is the U.S. Federal Government’s principal agency for cancer research and training. As the nation’s leading federal agency for cancer research, NCI has 30 divisions, offices, and centers that work together to build, maintain, and enhance a cohesive and comprehensive cancer research agenda. Their work ranges from cutting-edge research on cancer causes, treatment, and prevention; to training the next generation of cancer researchers; to funding and supporting the nation’s vast network of scientists and cancer research institutions; to informing and educating the American public and the world about cancer.

The aims of the European Organisation for Research and Treatment of Cancer (EORTC) are to develop, conduct, coordinate, and stimulate translational and clinical research in Europe to improve the management of cancer and related problems by increasing survival but also patient quality of life. Extensive and comprehensive research in this wide field is often beyond the means of individual European hospitals and can be best accomplished through the multidisciplinary multinational efforts of basic scientists and clinicians.

The ultimate goal of the EORTC is to improve the standard of cancer treatment through the testing of more effective therapeutic strategies based on drugs, surgery, and/or radiotherapy that are already in use. The EORTC also contributes to the development of new drugs and other innovative approaches in partnership with the pharmaceutical industry. This is accomplished mainly by conducting large, multicenter, prospective, randomized, phase III clinical trials. In this way, the EORTC facilitates the passage of experimental discoveries into state-of-the-art treatments.
ORGANIZING AND SCIENTIFIC COMMITTEES

ORGANIZING COMMITTEE COCHAIRS:

José Baselga
Memorial Sloan Kettering Cancer Center, New York, NY (AACR)*

James H. Doroshow, MD
National Cancer Institute, Bethesda, MD (NCI)*

Denis A. Lacombe
European Organisation for Research and Treatment of Cancer, Brussels, Belgium (EORTC)*

SCIENTIFIC COMMITTEE COCHAIRS:

Antoni Ribas
UCLA Medical Center, Los Angeles, CA (AACR)*

James L. Gulley
National Cancer Institute, Bethesda, MD (NCI)*

Charles Swanton
The Francis Crick Institute and UCL Cancer Institute, London, United Kingdom (EORTC)*

SCIENTIFIC COMMITTEE:

Jeffrey S. Abrams, NCI-DCTD, Rockville, MD
Ash A. Alizadeh, Stanford University, Stanford, CA
Rafael G. Amado, Adaptimmune, Philadelphia, PA
Gerhardt Attard, Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom
Alberto Bardelli, University of Turin School of Medicine/IRCCS, Candiolo, Italy*
Kevin M. Brindle, Cancer Research UK Cambridge Research Institute, Cambridge, United Kingdom
Emiliano Calvo, START Madrid, Madrid, Spain
Howard Y. Chang, Stanford University School of Medicine, Stanford, CA
Alice P. Chen, National Cancer Institute, Bethesda, MD
Jerry M. Collins, NCI-DCTD, Rockville, MD
Barbara A. Conley, NCI-DCTD, Rockville, MD
William L. Dahut, National Cancer Institute, Bethesda, MD
Kapil Dhingra, KAPital Consulting LLC, Sparta, NJ
Christian Dittrich, Kaiser Franz Josef-Spital, Vienna, Austria
Caroline Dive, Cancer Research UK Manchester Institute, Manchester, United Kingdom*
Jeffrey A. Engelman, Novartis, Cambridge, MA
Levi A. Garraway, Eli Lilly and Company, Indianapolis, IN
Mark R. Gilbert, NCI-CCR, Bethesda, MD*
John B.A.G. Haanen, Netherlands Cancer Institute, Amsterdam, The Netherlands
Toby Tucker Hecht, National Cancer Institute, Rockville, MD
Priti Hegde, Genentech, Inc., South San Francisco, CA
S. Percy Ivy, NCI-DCTD, Bethesda, MD
Paula M. Jacobs, Cancer Imaging Program, Bethesda, MD
Wendell Lim, UCSF, San Francisco, CA
Roger S. Lo, UCLA, Los Angeles, CA
Crystal L. Mackall, Stanford University School of Medicine, Stanford, CA*
Richard M. Marais, Cancer Research UK Manchester Institute, Manchester, United Kingdom
Elaine R. Mardis, Nationwide Children's Hospital, Columbus, OH
Christophe Massard, Institut Gustave Roussy, Villejuif, France
Paul S. Meltzer, NCI-CCR, Bethesda, MD
Garry P. Nolan, Stanford University School of Medicine, Stanford, CA
William Pao, Roche Pharma Research and Early Development, Basel, Switzerland*
Ruth Plummer, Newcastle University Northern Institute for Cancer Research, Newcastle Upon Tyne, United Kingdom
Yves G. Pommier, NCI-CCR, Bethesda, MD
Eric Raymond, Paris Saint-Joseph Hospital, Paris, France
Neal Rosen, Memorial Sloan Kettering Cancer Center, New York, NY
Robert D. Schreiber, Washington University School of Medicine, St. Louis, MO
Patricia S. Steeg, National Cancer Institute, Bethesda, MD*
Beverly A. Teicher, National Cancer Institute, Bethesda, MD
Sabine Tejpar, University of Leuven, Leuven, Belgium
Samra Turajlic, The Royal Marsden NHS Foundation Trust, London, United Kingdom
Anna M. Wu, David Geffen School of Medicine at UCLA, Los Angeles, CA
James A. Zwiebel, National Cancer Institute CTEP-DCTD, Rockville, MD

*denotes member of the Executive Committee
THURSDAY, OCTOBER 26

3:00 p.m.-6:00 p.m.  REGISTRATION

FRIDAY, OCTOBER 27

7:00 a.m.-5:00 p.m.  REGISTRATION

8:00 a.m.-9:00 a.m.  CONTINENTAL BREAKFAST

9:00 a.m.-10:30 a.m.  EDUCATIONAL SESSION: MOLECULAR TUMOR BOARDS
    Session Cochairs: Elaine R. Mardis, Nationwide Children’s Hospital, Columbus, OH, and Josep Tabernero, Vall d’Hebron University Hospital, Barcelona, Spain

10:30 a.m.-10:50 a.m.  BREAK

10:50 a.m.-12:20 p.m.  LATE-BREAKING RESEARCH SESSION

12:20 p.m.-1:45 p.m.  LUNCH ON OWN

1:50 p.m.-2:00 p.m.  WELCOME AND OPENING REMARKS
    • Antoni Ribas, UCLA Medical Center, Los Angeles, CA
    • James L. Gulley, National Cancer Institute, Bethesda, MD
    • Charles Swanton, The Francis Crick Institute and UCL Cancer Institute, London, United Kingdom

*Subject to change. Visit www.AACR.org/Targets17 for an updated program schedule.
2:00 p.m.-4:10 p.m.  KEYNOTE LECTURES
    • Lewis C. Cantley, Weill Cornell Medical College, New York-Presbyterian Hospital, New York, NY
    • Ton Schumacher, Netherlands Cancer Institute, Amsterdam, The Netherlands
    • Steven A. Rosenberg, National Cancer Institute, Bethesda, MD

4:10 p.m.-4:30 p.m.  BREAK

4:30 p.m.-6:30 p.m.  PLENARY SESSION 1: ACQUIRED RESISTANCE TO CHECKPOINT INHIBITORS
    Session Cochairs: Alberto Bardelli, University of Turin School of Medicine/IRCCS, Candiolo, Italy, and
    Antoni Ribas, UCLA Medical Center, Los Angeles, CA

7:00 p.m.-8:30 p.m.  OPENING RECEPTION

SATURDAY, OCTOBER 28

7:00 a.m.-8:00 a.m.  CONTINENTAL BREAKFAST

7:00 a.m.-5:00 p.m.  REGISTRATION

8:00 a.m.-10:00 a.m.  PLENARY SESSION 2: DEFINING AND TARGETING CANCER NEOEPITOPES
    Session Cochairs: Catherine J. Wu, Dana-Farber Cancer Institute, Boston, MA, and
    Cochair to be announced

10:00 a.m.-10:20 a.m.  BREAK

10:20 a.m.-12:20 p.m.  PLENARY SESSION 3: CHALLENGES AND OPPORTUNITIES OF GENOMIC-BASED
    CLINICAL TRIALS
    Session Cochairs: James L. Gulley, National Cancer Institute, Bethesda, MD, and
    José Baselga, Memorial Sloan Kettering Cancer Center, New York, NY

12:30 p.m.-4:00 p.m.  POSTER SESSION A

12:30 p.m.-5:30 p.m.  EXHIBIT SHOW
PROGRAM SCHEDULE*

4:30 p.m.-6:00 p.m.  CONCURRENT SESSIONS 1-4

Concurrent Session 1: Aneuploidy as a Driver of Cancer Evolution  
Session Cochairs: Charles Swanton, The Francis Crick Institute and UCL Cancer Institute, London, United Kingdom, and Samuel F. Bakhomou, Memorial Sloan Kettering Cancer Center, New York, NY

Concurrent Session 2: CNS Penetration of Drugs  
Session Cochairs: E.G. Elisabeth de Vries, University Medical Centre, Groningen, The Netherlands, and Patricia S. Steeg, National Cancer Institute, Bethesda, MD

Concurrent Session 3: Mechanistic Principles of Cancer Cells  
Session Cochairs: Andrea Califano, Columbia University, New York, NY, and Cochair to be announced

Concurrent Session 4: Metastatic Microenvironment  
Session Cochairs: Ilaria Malanchi, The Francis Crick Institute, London, United Kingdom, and Cochair to be announced

SUNDAY, OCTOBER 29

7:00 a.m.-8:00 a.m.  CONTINENTAL BREAKFAST

7:00 a.m.-5:00 p.m.  REGISTRATION

8:00 a.m.-10:00 a.m.  PLENARY SESSION 4: DECIPHERING THE COMPLEXITY OF THE TUMOR MICROENVIRONMENT  
Session Cochairs: Michael Angelo, Stanford University School of Medicine, Palo Alto, CA and Cochair to be announced

10:00 a.m.-10:20 a.m.  BREAK

10:20 a.m.-12:20 p.m.  PLENARY SESSION 5: EPIGENETICS  
Session Cochairs to be announced

12:30 p.m.-4:00 p.m.  POSTER SESSION B

12:30 p.m.-5:30 p.m.  EXHIBIT SHOW

4:30 p.m.-6:00 p.m.  CONCURRENT SESSIONS 5-8

Concurrent Session 5: DNA Damage and Repair  
Session Cochairs: Serena Nik-Zainal, Wellcome Trust Sanger Institute, Cambridge, United Kingdom, and Yves G. Pommier, NCI-CCR, Bethesda, MD

Concurrent Session 6: Metabolism  
Session Cochairs: W. Marston Linehan, National Cancer Institute, Bethesda, MD, and Cochair to be announced

*Subject to change. Visit www.AACR.org/Targets17 for an updated program schedule.
Concurrent Session 7: The Role of Non-mutated Genes in Cancer Biology
Session Cochairs: Thomas Babletz, University of Erlangen, Erlangen, Germany, and Claudia Palena, National Cancer Institute, Bethesda, MD

Concurrent Session 8: Tracking Cancer in the Blood
Session Cochairs: Maximilian Diehn, Stanford University, Stanford, CA, and Caroline Dive, Cancer Research UK Manchester Institute, Manchester, United Kingdom

MONDAY, OCTOBER 30

7:00 a.m.-8:00 a.m. CONTINENTAL BREAKFAST

7:00 a.m.-12:00 p.m. REGISTRATION

8:00 a.m.-10:00 a.m. PLENARY SESSION 6: CAR-T THERAPY
Session Cochairs: Martin Pule, Autolus, London, United Kingdom, and Michel Sadelain, Memorial Sloan Kettering Cancer Center, New York, NY

10:00 a.m.-10:20 a.m. BREAK

10:20 a.m.-12:20 p.m. PLENARY SESSION 7: DRUGGING THE UNDRUGGABLE/HISTORICALLY CHALLENGING TARGETS
Session Cochairs: Neal Rosen, Memorial Sloan Kettering Cancer Center, New York, NY, and Jeffrey A. Engelman, Novartis, Cambridge, MA

12:20 p.m.-12:30 p.m. CLOSING REMARKS
When submitting an abstract for the 2017 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics conference using the Online Abstract Submission System, authors will be asked to choose the appropriate category that best describes the scientific content of the abstract. This information will be used as a guide by the members of the Scientific Committee in their review of abstracts. Before making a selection, authors should review the entire list below for the most appropriate abstract category.

- Angiogenesis and antiangiogenesis agents
- Animal models
- Apoptosis, necrosis, and autophagy
- Bioinformatics
- Biomarkers
- Cancer stem cells
- Cell cycle regulators
- Cellular responses to therapy
- Chemistry
- Chemoprevention
- Clinical trials
- DNA repair and modulation
- Drug delivery
- Drug design
- Drug metabolism, transport, and biodistribution
- Drug resistance and modifiers
- Drug screening
- EGFR/Her2
- Epigenetic regulation of tumor immunity
- Epigenetic targets
- Gene therapies
- Genomics, proteomics, and target discovery
- Heat shock proteins
- Hormonal agents and therapy
- Imaging
- Immune checkpoints
- Immune mechanisms invoked by radiation therapy
- Immune modulators
- Immune monitoring/clinical correlates
- Immune response to therapies
- In vitro and in vivo models for targets
- MAPK pathways
- Metabolism
- Metastasis and invasion
- Molecular classification of tumors
- Monoclonal antibodies
- mTOR/P13-kinase
- Natural products
- New molecular targets
- Novel assay technology
- Pediatric-early drug development
- Pharmacogenetics, pharmacogenomics, and therapeutic response
- Pharmacokinetics and pharmacodynamics
- Protein-protein interaction
- Radiotherapeutics
- RNA and RNA-based technologies and therapies
- Signal transduction modulators
- Target identification and validation
- Therapeutic agents: biological
- Therapeutic agents: other
- Therapeutic agents: small-molecule kinase inhibitors
- Topoisomerase inhibitors
- Toxicology
- Tubulin-interacting agents
- Tumor immunology targets
- Tumor microenvironment
- Tumor suppressors
- Other
GUIDELINES FOR PREPARATION AND SUBMISSION OF ABSTRACTS
(Submission deadline: 11:59 p.m. U.S. Eastern Time, Sunday, July 23, 2017)

Authors must submit abstracts for presentation at the 2017 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics conference using the AACR Online Abstract Submission System, which will be available at www.AACR.org/Targets17 beginning Wednesday, May 24, 2017. You can create, modify, and submit abstracts until the Sunday, July 23, submission deadline. Complete instructions on the use of the AACR Online Abstract Submission System will be provided online.

The Abstract Submission System has been optimized for the current versions of most browsers, including: Google Chrome version 33 or higher; Internet Explorer version 8.0 or higher; Firefox version 16 or higher; and Safari version 5.0 or higher. Browsers should be set to enable JavaScript and to accept cookies.

Users who need assistance in properly updating and configuring their browsers should contact Abstract Submission Customer Service at 217-398-1792 or support@abstractsonline.com.

CONTENT OF ABSTRACTS
Authors who submit abstracts confirm that they have not previously published these data, that they have not previously presented them at a large national annual scientific meeting, and that they are not planning to present or publish them prior to the dates of the 2017 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics conference. Each abstract should contain: (a) an introductory sentence indicating the purposes of the study; (b) a brief description of pertinent experimental procedures; (c) a summary of the new, unpublished data; and (d) a statement of the conclusions.

Authors must accept sole responsibility for the statements in their abstracts. Abstracts should be carefully proofread to avoid errors in the published literature. American spelling should be used throughout; for more information regarding American spelling, please refer to Scientific Style and Format: The CSE Manual for Authors, Editors, and Publishers, Eighth Edition (Council of Science Editors, 2014).

COPYRIGHT TRANSFER/ABSTRACT PRESENTATION
On behalf of all authors, the corresponding author must:

1. Transfer copyright of the abstract to the AACR for publication; and

2. Confirm that an author will attend the 2017 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics conference to present the abstract.

ABSTRACT CONTROL NUMBER
An abstract control number (e.g., 17-A-1234-AACR) will be assigned to each abstract submitted online and will be listed on all email correspondence regarding the abstract. Please refer to the Abstract Control Number in any abstract communications.

FINANCIAL RELATIONSHIPS OF COAUTHORS
Per ACCME regulations, the AACR must collect information on the financial relationships of all meeting presenters and abstract authors. You will be asked to disclose your financial relationships and the financial relationships of all of your coauthors. For more information on financial relationships, visit www.AACR.org/cme.

LENGTH OF ABSTRACTS
The combined length of the abstract body, title, and tables may not exceed 3,000 characters, not including spaces and the author string. Tables count for 800 characters against the limit. Submission cannot be completed for abstracts that exceed this limit.

DISCLOSURE OF CHEMICAL STRUCTURES
At the time of abstract submission, the submitting author is required to state whether chemical compounds were used in the scientific work to generate the data in the proffered paper. Chemical compounds are defined as low-molecular-weight (generally <1000 g/mol) organic or inorganic molecules, peptides, or proteins/nucleic acids co-crystallized with low-molecular-weight molecules. If chemical compounds were used, the corresponding author is further required to indicate whether the complete chemical structures of the compounds used will be disclosed at the time of presentation at the meeting. The chemical structures are not required to be included at the time of abstract submission; rather, an indication of the intent to disclose any such structures at the time of presentation is required. The Scientific Committee will then evaluate the information provided by the corresponding author and determine the acceptability of the proffered paper for presentation. Those who do not intend to disclose chemical structures may have their abstracts rejected for participation; however, a limited number of these abstracts may be accepted for presentation if deemed to be of sufficient scientific merit.
ABSTRACT SUBMISSION CATEGORIES AND GUIDELINES

DEADLINE FOR WITHDRAWAL OF ABSTRACTS
The AACR cannot comply with any request for withdrawal of an abstract that will delay the publication of the Program. However, requests to withdraw abstracts will be accepted through Friday, September 1, 2017. Withdrawal requests must be sent by email to abstract@aacr.org. Withdrawal requests must include the abstract control number and title as well as an explanation of the reason for withdrawal.

GUIDELINES FOR PREPARATION AND SUBMISSION OF LATE-BREAKING ABSTRACTS
Late-breaking abstract submission opens: Monday, August 28, 2017
Late-breaking abstract submission deadline: 11:59 p.m. U.S. Eastern Time, Thursday, September 7, 2017

LATE-BREAKING ABSTRACT SUBMISSION PROCESS
Abstracts that contain new data (unavailable at the time of the July 23 regular submission deadline) may be submitted as late-breaking abstracts beginning on Monday, August 28. Submissions must be completed by Thursday, September 7, 2017. Late-breaking abstracts will be considered for both oral and poster presentations.
Authors must submit late-breaking abstracts for presentation at the 2017 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics conference using the AACR Online Abstract Submission System, which will be available at www.aacr.org/Targets17 beginning Monday, August 28, 2017. You can create, modify, and submit abstracts until 11:59 p.m. U.S. Eastern Time on Thursday, September 7. Complete instructions on the use of the AACR Online Abstract Submission System will be provided online.
A special subcommittee of the Scientific Committee will evaluate the merit of late-breaking abstracts.

DEADLINE FOR WITHDRAWAL OF LATE-BREAKING ABSTRACTS
The AACR cannot comply with any request for withdrawal of a late-breaking abstract that will delay the publication of the Program. However, requests to withdraw abstracts will be accepted through Wednesday, September 27, 2017. Withdrawal requests must be sent by email to abstract@aacr.org. Withdrawal requests must include the abstract control number and title as well as an explanation of the reason for withdrawal.

OPPORTUNITIES FOR SHORT TALKS FROM ABSTRACTS AND LATE-BREAKING ABSTRACTS
A subcommittee of the Scientific Committee will evaluate highly rated abstracts and late-breaking abstracts and, where thematically appropriate, invite authors to present a short talk during the program. All accepted abstracts are eligible. Not all sessions will include short talks.

RELEASE DATE FOR ABSTRACTS AND LATE-BREAKING ABSTRACTS
All accepted abstracts are scheduled to be posted online via the online planner and app on Monday, October 16, 2017 (with the exception of those abstracts and late-breaking abstracts selected for inclusion in the AACR press program). Accepted late-breaking abstracts will be posted on Wednesday, October 25. Abstracts will not be available before these dates.

PRESENTATION OF ABSTRACTS AND LATE-BREAKING ABSTRACTS
Every abstract and late-breaking abstract that has been accepted for publication in the online Proceedings must also be presented at the meeting. Specifically, the author listed as the presenter must register for the meeting and attend the session in which the abstract is scheduled to discuss in detail the research outlined in the published abstract, according to the specific guidelines of the session. If, due to unforeseen circumstances, the designated presenter is unavailable to attend the session to present the abstract, he or she must contact the AACR Program Development Department to designate a coauthor to serve as the presenter. If no authors are available to present the abstract, the presenter must withdraw the abstract by submitting a withdrawal request by email to abstract@aacr.org. Withdrawal requests must include the abstract control number and title as well as an explanation of the reason for withdrawal.

Failure to comply with these regulations pertaining to abstract presentation may result in actions including, but not limited to:
• The withdrawal of the abstract or late-breaking abstract from the session
• The removal of the abstract or late-breaking abstract from the online Proceedings
• The loss of future abstract or late-breaking abstract submission/authorship privileges for the presenter of the abstract or late-breaking abstract
# ACCOMMODATIONS AND TRAVEL

The conference will be held at the Pennsylvania Convention Center, located in the heart of Center City Philadelphia and just 12 miles/19 km from Philadelphia International Airport.

The AACR has contracted with several hotels to offer reduced room rates for attendees at this year’s conference. The Philadelphia Marriott Downtown will serve as the headquarter hotel for the 2017 Molecular Targets and Cancer Therapeutics conference, with the Loews Philadelphia Hotel and Courtyard Philadelphia Downtown also serving as official conference hotels. Please review the pricing options below and the map on page 12 before making reservations.

Hotel reservations can be made by phone or online through AACR Housing. AACR Housing will open Wednesday, June 21, 2017 and accept reservations through Monday, September 25, 2017. After September 25, reservations and rates will be subject to hotel availability. Room reservations must be guaranteed with a major credit card. To make a reservation please visit the Accommodations and Travel webpage at [www.AACR.org/Targets17](http://www.AACR.org/Targets17).

<table>
<thead>
<tr>
<th>Map Number</th>
<th>Hotels</th>
<th>Single/Double Rate</th>
<th>Triple/Quad Rate</th>
<th>Smoke-Free Hotel</th>
<th>Distance from Convention Center</th>
<th>Business Center</th>
<th>Coffee Maker</th>
<th>High-Speed Internet</th>
<th>Onsite Fitness Center</th>
<th>Indoor/Outdoor Pool</th>
<th>Restaurants</th>
<th>Bars</th>
<th>Room Service</th>
<th>Comp. Breakfast</th>
<th>Self Parking</th>
<th>Valet Parking</th>
<th>Room Rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td><strong>Philadelphia Marriott Downtown</strong>&lt;br&gt;1201 Market St.</td>
<td>$259/&lt;br&gt;$259</td>
<td>$279/&lt;br&gt;$299</td>
<td>Yes</td>
<td>Less than 1 block</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Indoor 1</td>
<td>1</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>$49</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td><strong>Courtyard Philadelphia Downtown</strong>&lt;br&gt;21 North Jupiter St.</td>
<td>$229/&lt;br&gt;$229</td>
<td>$249/&lt;br&gt;$269</td>
<td>Yes</td>
<td>2 blocks</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Indoor 1</td>
<td>1</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>$42</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td><strong>Loews Philadelphia Downtown</strong>&lt;br&gt;1200 Market St.</td>
<td>$239/&lt;br&gt;$239</td>
<td>$264/&lt;br&gt;$289</td>
<td>Yes</td>
<td>Less than 1 block</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Indoor 1</td>
<td>1</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>$49</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Room rates are in U.S. Dollars.

For more information on the convention center and conference hotels, please visit [www.AACR.org/Targets17](http://www.AACR.org/Targets17) and follow the link for Accommodations and Travel.
TRAVEL TO PHILADELPHIA

The closest major airport to the Pennsylvania Convention Center and conference hotels is Philadelphia International Airport (PHL), located approximately 12 miles/19 km (20-25 minutes) from the Pennsylvania Convention Center.

The AACR has named Gant Travel Management as its official travel coordinator for this conference. Gant will provide custom itineraries with the lowest applicable airfares and best journey time. Fly on United Airlines, the official airline of this conference, and save with special discounts exclusive to attendees and guests. Full mileage credit will be earned by frequent flyer club members.

To receive the exclusive discounts, please contact Gant toll-free at 877-924-2298 (630-227-3818 if outside of the U.S./Canada) or by email at aacr@ganttravel.com.

Gant is open from 7:30 a.m. to 6:00 p.m. U.S. Central Time, Monday through Friday.

Amtrak train service is also readily available for attendees traveling from the Eastern U.S. to Philadelphia. Amtrak’s 30th Street Station is approximately 1.4 miles from the Pennsylvania Convention Center.

For additional information on travel to Philadelphia and ground transportation once you arrive, please visit www.AACR.org/Targets17 and follow the link for Accommodations and Travel.

INTERNATIONAL TRAVEL

Researchers from more than 50 different countries around the world regularly participate in this joint AACR-NCI-EORTC conference. If you plan to attend the 2017 Molecular Targets and Cancer Therapeutics conference, please contact the American Consulate in your country to review the current regulations for travel to the United States. Obtaining the proper documentation may take several weeks or months, depending on your location, so please contact the consulate as soon as possible if you are considering attending this conference. Information is also available on the U.S. Department of State website at www.travel.state.gov.
CONTINUING MEDICAL EDUCATION (CME)

The AACR’s Continuing Medical Education (CME) Program brings the latest cancer research from “bench to bedside and back.” The AACR has been awarded Full Accreditation status from the Accreditation Council for Continuing Medical Education (ACCME). The CME Program consists of educational interventions designed to encourage the analysis and discussion of the latest findings in all areas of basic, translational, and clinical cancer research not only among researchers, but also by engaging clinicians in this scientific discourse. The AACR is committed to advance the ability of clinicians to apply critical aspects of cancer research to the clinical practice of oncology to aid in the detection, diagnosis, treatment, and prevention of cancer.

Continuing Medical Education Activity-AMA PRA Category 1 Credits™ will be available. Details will be available online at www.AACR.org/Targets17.
FINANCIAL SUPPORT FOR ATTENDANCE

AACR SCHOLAR-IN-TRAINING AWARDS

AACR Associate Members in good standing who submit abstracts may be considered for a Scholar-in-Training Award to offset a portion of the registration, travel, and subsistence expenses incurred in attending this conference. The number of awards provided and the dollar amounts of each award will be based on available funding. The award application deadline is Sunday, July 23. Additional information and application instructions will be available online at www.AACR.org/Targets17.

AACR MINORITY SCHOLAR IN CANCER RESEARCH AWARDS

Presenters of a proffered paper who are full-time predoctoral (graduate or medical) students, residents, and clinical or postdoctoral fellows who are engaged in cancer research or have the training and potential to make contributions to this field are encouraged to apply for this meritorious scholar award. Supported by a generous grant from the Center to Reduce Cancer Health Disparities of the National Cancer Institute, this program applies only to racial/ethnic minority groups that have been identified by the NCI as being traditionally under-represented in cancer and biomedical research, i.e., African American/Black, Alaskan Native, Hispanic/Latino, Native American, and Native Pacific Islander. Only citizens of the United States or Canada or scientists who are permanent residents of these countries may receive one of these awards. The award application deadline is Monday, July 24, 2017. Additional information and application instructions are available online at www.AACR.org/Targets17.

AACR MINORITY AND MINORITY-SERVING INSTITUTION (MMSI) FACULTY SCHOLAR IN CANCER RESEARCH AWARDS

Full-time minority faculty and faculty of Minority-Serving Institutions (Historically Black Colleges and Universities [HBCUs], Hispanic-Serving Institutions [HSIs], American Indian Tribally-Controlled Colleges and Universities [AITCCUs], and other postsecondary institutions as defined by the U.S. Department of Education) who present a proffered paper at this conference are encouraged to apply for this meritorious scholar award. Supported by a generous grant from the Center to Reduce Cancer Health Disparities of the National Cancer Institute, the purposes of these awards are to increase the scientific knowledge base of minority faculty and faculty at MSIs, to encourage them in their research, and to assist in inspiring their students to pursue careers in cancer research. Only citizens of the United States or Canada or scientists who are permanent residents of these countries may receive one of these awards. The award application deadline is Monday, July 24, 2017. Additional information and application instructions are available online at www.AACR.org/Targets17.
Individuals wishing to attend the conference can register online at [www.aacr.org/Targets17](http://www.aacr.org/Targets17) or by returning the registration form on pages 23-24 of this brochure. Attendee registration includes admission to all scientific sessions, poster sessions, the opening reception on October 27, conference continental breakfasts on October 27, 28, 29, and 30, and coffee breaks. Registration also provides individual access to the 2017 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Webcast and one complimentary drink ticket to the opening reception on October 27. All registrants agree to follow the Code of Conduct, Policies, and Procedures for the conference outlined on page 17 of this brochure.

Registration will not be processed without full payment. Government or other payment orders are not accepted. All payments must be in U.S. currency, drawn on a U.S. bank. Visa, MasterCard, and American Express are also accepted for payment. Places at the conference are on a first-come, first-served basis, according to the date of registration. On-site registration will be available at the Pennsylvania Convention Center beginning Thursday, October 26 at 3:00 p.m. All registrations are for the full conference.

Requests for refunds must be made in writing and received by Friday, September 29, 2017. Refund requests may be sent by email to molecular@compusystems.com. There will be a $125 administrative fee for processing cancellations received by September 29. After September 29, no refunds can be made.

### SURVIVOR AND PATIENT ADVOCATE OPPORTUNITIES

The AACR strongly encourages the involvement of survivors and patient advocates in this conference and is pleased to offer discounted registration rates to this group. Advocates must submit a biography or a curriculum vitae and the advocate verification form to receive the discounted rate. You can find the advocate verification form online at [www.AACR.org/SurvivorsAndAdvocates](http://www.AACR.org/SurvivorsAndAdvocates). Please contact Karen Russell Mills at advocacy@aacr.org or 215-446-7104 for further information. On-site registration at this special rate will not be available.

<table>
<thead>
<tr>
<th>Category</th>
<th>Early Until August 22</th>
<th>Advance August 23-September 22</th>
<th>Regular After September 22</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>AACR and EORTC Members</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Active/Affiliate (Nonprofit)</td>
<td>$785</td>
<td>$970</td>
<td>$985</td>
</tr>
<tr>
<td>Active/Affiliate (Industry)</td>
<td>$945</td>
<td>$1,115</td>
<td>$1,255</td>
</tr>
<tr>
<td>Associate (predoctoral, postdoctoral</td>
<td>$445</td>
<td>$595</td>
<td>$615</td>
</tr>
<tr>
<td>and clinical fellows)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Emeritus</td>
<td>$445</td>
<td>$595</td>
<td>$615</td>
</tr>
<tr>
<td>Patient Advocate</td>
<td>$175</td>
<td>$200</td>
<td>$225</td>
</tr>
<tr>
<td><strong>Nonmembers</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nonprofit</td>
<td>$1,065</td>
<td>$1,185</td>
<td>$1,225</td>
</tr>
<tr>
<td>Industry</td>
<td>$1,265</td>
<td>$1,395</td>
<td>$1,515</td>
</tr>
<tr>
<td>Pre-/Postdoctoral Student</td>
<td>$525</td>
<td>$625</td>
<td>$680</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patient Advocate</td>
<td>$225</td>
<td>$250</td>
<td>$275</td>
</tr>
</tbody>
</table>

*Nonmember pre-/postdoctoral students must have their registrar, dean, or department head certify that they are enrolled at the university and working toward a degree or fellowship in a field related to cancer research.*
AACR MEMBERSHIP
AACR membership is available to individuals who are interested in joining the AACR and being a part of a dynamic and vibrant organization that offers its members benefits, programs, and activities that promote the exchange of timely scientific information and excellent opportunities to participate more fully in the global conquest of cancer by fostering important relationships and collaborations with cancer scientists internationally. The AACR is also eager to support the exchange of knowledge and research with investigators who are in countries with emerging economies. Significantly reduced membership dues are available for these investigators.

ELIGIBILITY FOR REGISTRATION AT AACR AND EORTC MEMBER RATES
Nonmember individuals interested in joining the AACR and registering at the early registration rate must submit membership applications no later than August 16, 2017. Individuals who are interested in joining the AACR and registering at the advance registration member rate must submit membership applications no later than September 15, 2017. Only individuals who are listed on the membership rolls as members in good standing as of October 20, 2017, will be accorded the privilege of registering for the conference at the member rates noted on the registration form. If, upon review of the membership application, a candidate is deemed ineligible for the membership category to which he or she has applied, then the candidate will need to register at the nonmember rate. Membership information and the Membership Application form can be downloaded from the AACR website at www.AACR.org/Membership. Contact the Membership Department at 215-440-9300 or membership@aacr.org with any questions.

ASSISTANCE FOR ATTENDEES WITH DISABILITIES
This AACR-NCI-EORTC conference is accessible to all registrants. Attendees with special requirements for transportation, hotel accommodations, or other facilities associated with the conference should notify the AACR in advance when registering or by emailing meetings@aacr.org.

LOCATION
The conference will be held at the Pennsylvania Convention Center located in the heart of Center City Philadelphia. The Convention Center’s convenient location in the heart of downtown Philadelphia makes it easy to explore the city’s neighborhoods. Feel like a Philadelphian as you walk day and night through the vibrant streetscape and immerse yourself in America’s Old and New World. Picturesque and friendly streets are lined with parks, rivers, shops, public art, restaurants and museums. Everything is within walking distance. From the biggest name brands to independent boutiques, not only is shopping in Philadelphia world-class, but clothing and shoe purchases are tax-free! Visit www.discoverphi.com/deals/ to take advantage of local deals specifically designed for convention attendees.

Philadelphia is the city where the American Dream was founded. Philadelphia is where courageous visionaries crafted the model for modern-day democracy that inspires people globally to embrace the power of their individuality and our human potential. Philadelphia is home to iconic places such as Independence Hall, a UNESCO World Heritage Site that changed the world when the fathers of our nation used the location to debate and adopt both the Declaration of Independence and the U.S. Constitution.
You will be captivated by a 21st-century city where an inspired, young, creative culture is blooming and partnering with innovators and educators. With a spirit of independence, the city and region are giving birth to a new generation of energized people designing this Modern Renaissance City.

CODE OF CONDUCT, POLICIES, AND PROCEDURES

The AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics conference will bring together an estimated 2,500 representatives from academia, industry, government, and advocacy organizations from across the globe. In order for all participants to have the opportunity to gain the most benefit from this conference, the AACR is committed to providing a safe and secure environment. Please review the following policies and procedures for conference participants. By registering for the 2017 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics meeting, you agree to the following terms:

• NEW AACR Policy Regarding Photography. Effective April 1, 2017, conference attendees may take photographs during oral or poster presentations provided that the photographs are strictly for personal, noncommercial use and are not to be published in any form. Attendees are prohibited from using flash photography or otherwise distracting the presenters or members of the audience.

• NEW AACR Policy Regarding Social Media. Conference attendees may share information from presentations on social media provided that they respect the wishes of presenters. Oral presenters may label any or all slides in their presentations with “DO NOT POST.” Similarly, poster presenters may label their posters with “DO NOT POST.” Attendees must respect the presenters’ requests in these instances; while attendees may take photographs of all slides and posters, they must refrain from posting on social media any images from slides or posters labeled “DO NOT POST.”

• The AACR prohibits intimidating, threatening, or harassing conduct of any kind during this program. This applies to all participants—attendees, presenters, exhibitors, staff, vendors, etc.

• The AACR is committed to a safe, hospitable, and productive environment for all participants of this program, regardless of age, disability, ethnicity, gender, religion, or sexual orientation.

• The AACR expects all participants to communicate professionally and constructively, handling dissent and disagreement with courtesy, dignity, and an open mind, being respectful when providing feedback, and being open to alternative points of view.

• Children under 12 years of age are not permitted in any scientific session, poster session, the exhibit hall, or any official event taking place at this program at any time. Children cannot be left unattended or unsupervised in the Convention Center.

• Cell phones and other electronic devices must be turned off or placed on “silent” mode before entering a session. Participants should step out of session rooms to make calls, which is distracting to other participants.

• The AACR expects participants to share information about this program responsibly and clearly distinguish individual opinion from fact.

• A professional photographer and videographer will be on site to document conference events and activities between October 26 and October 30, 2017. Photographs and video footage are the sole property of the AACR. By registering for and attending these events, attendees understand that the AACR may use their likenesses for future promotional purposes. If you do not wish to be photographed, please notify the photographer and/or videographer on-site.

• Participants must obey all applicable laws and regulations of the relevant government authorities while attending this program. Participants must comply with all applicable safety guidelines related to the conference venue.

• If a session room becomes too crowded, the AACR asks you to follow instructions provided by the AACR staff, Convention Center staff, or security. Instructions may include not standing against the walls, not blocking the aisles or doors, or being denied entry if the room becomes too crowded. The AACR and all participants are obligated to abide by the guidelines established by the Fire Marshal in the Convention Center. If a room reaches full capacity and there is not full cooperation, the Fire Marshal has the authority to delay or terminate the session.

• The AACR encourages responsible drinking for those drinking alcohol. Beer and wine will be offered at some official social events. Alcohol will not be served to anyone under the age of 21. Alcoholic beverages are allowed in specific areas and must not be taken out of these areas.
Members of the national and international media rely on the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics conference to provide the most up-to-date information on drug development in oncology. At this year’s conference, the American Association for Cancer Research (AACR) Communications and Public Relations Department will be conducting a press program and staffing a press room. Reporters and PIOs from cancer and medical centers who are interested in registering for the conference should contact Lauren Riley at lauren.riley@aacr.org. The AACR does not release media lists, but will make available company-sponsored press releases on abstract presentations in the press room. For more information on the Molecular Targets and Cancer Therapeutics press program, contact Jeff Molter at 267-210-3965 or jeff.molter@aacr.org, Julia Gunther at 215-446-6896 or julia.gunther@aacr.org, or Lauren Riley at 215-446-7155 or lauren.riley@aacr.org.
CALL FOR ABSTRACTS | Abstract Submission Deadline: July 23, 2017
The AACR Foundation welcomes support from individuals, foundations, corporations, and other organizations interested in bringing this important international education program to an estimated 3,000 conference participants from across the U.S. and the world. Our conference supporters enjoy recognition in the Molecular Targets and Cancer Therapeutics program, as well as acknowledgment on the AACR website promoting the conference. Additionally, the AACR Foundation acknowledges your generous support in on-site signage throughout the conference venue. At the conference, you will enjoy interacting face to face with cancer research professionals—academics, scientists, and pharmaceutical industry representatives—to discuss innovations in drug development, target selection, and the impact of new discoveries in molecular biology.

For information about supporting this important conference, please contact:

**AACR FOUNDATION**

Peter VanPelt, Director, Corporate Alliances
peter.vanpelt@aacr.org
215-446-7256

**PROFESSIONAL EDUCATIONAL GRANTS CONTINUING MEDICAL EDUCATION (CME)**

Ronald Arthur, Senior Manager, Office of CME
ronald.arthur@aacr.org
215-446-7139
EXHIBIT INFORMATION

Opportunities are available to reserve an exhibit space at this conference. Over 3,000 scientists and researchers who are leading the discovery and drug development effort against cancer worldwide are expected to attend this year’s conference. Don’t miss this opportunity to further your business by meeting new contacts from industry, government, and academia. AACR Annual Meeting Exhibitors receive an additional priority point for reserving a booth at this conference. Booths are assigned on a first-come, first-served basis, so be sure to get your application in before space is sold out. For further information please contact LaShanna Mackey, AACR Senior Meetings and Exhibits Coordinator, at 215-440-9300 or exhibits@aacr.org.
NEW! FREE ACCESS FOR CONFERENCE REGISTRANTS

As in previous years, the AACR will make a limited number of selected session webcasts free to all interested researchers. In addition, all paid registrants will receive exclusive online streaming access to the audio and slides of all scientific sessions presented at the 2017 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics conference.*

- Presentation slides synchronized with recorded audio presentations
- Speakers’ mouse movements captured and included in playback
- Available on compatible mobile devices and smart phones such as Android, iPad, iPod Touch, and iPhone
- Presentations searchable by session title, presentation title, and speaker name
- Exclusive access to online content for 15 months after the conference

*Participation in the 2017 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics webcasts is left to the discretion of each speaker. As a result, some presentations may not be available for webcast, and some webcast presentations may not include all slides. Sessions will not be streamed live. Selected session webcasts will be made available free within 24 hours, and the remaining webcasts will be made available on November 13, 2017. Registrants will receive login information via email on that date.
CALL FOR ABSTRACTS | Abstract Submission Deadline: July 23, 2017
### REGISTRATION RATES

(Includes full individual access to the 2017 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Webcast)

<table>
<thead>
<tr>
<th></th>
<th>Early Until August 22</th>
<th>Advance August 23-September 22</th>
<th>Regular/Onsite After September 22</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>AACR and EORTC Members</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Active/Affiliate (Nonprofit)</td>
<td>$795</td>
<td>$970</td>
<td>$985</td>
</tr>
<tr>
<td>Active/Affiliate (Industry)</td>
<td>$945</td>
<td>$1,115</td>
<td>$1,255</td>
</tr>
<tr>
<td>Associate (Pre-/Postdoctoral Student and Clinical Fellows)</td>
<td>$445</td>
<td>$595</td>
<td>$615</td>
</tr>
<tr>
<td>Emeritus</td>
<td>$445</td>
<td>$595</td>
<td>$615</td>
</tr>
<tr>
<td>Patient Advocate</td>
<td>$175</td>
<td>$200</td>
<td>$225</td>
</tr>
<tr>
<td><strong>Nonmembers</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nonprofit</td>
<td>$1,065</td>
<td>$1,185</td>
<td>$1,225</td>
</tr>
<tr>
<td>Industry</td>
<td>$1,265</td>
<td>$1,395</td>
<td>$1,515</td>
</tr>
<tr>
<td>Pre-/Postdoctoral Student¹</td>
<td>$525</td>
<td>$625</td>
<td>$680</td>
</tr>
<tr>
<td>Patient Advocate²</td>
<td>$225</td>
<td>$250</td>
<td>$275</td>
</tr>
</tbody>
</table>

**TOTAL ENCLOSED OR CHARGED US$**

Nonmember individuals interested in joining AACR and registering at the early registration rate must submit an application no later than **August 16, 2017**. Those individuals interested in registering at the advance registration rate must submit applications no later than **September 15, 2017**. Only individuals who are listed on the membership rolls as of **October 20, 2017**, will be accorded the privilege of registering for the conference at the member rates noted on the registration form. If, upon review of the membership application, a candidate is deemed ineligible for the membership category to which he or she has applied then the candidate will need to register at the nonmember rate. Membership information and the application form can be downloaded from the AACR website at www.AACR.org/Membership. Contact the AACR Membership Department at 215-440-9300 or membership@aacr.org with any questions.

**Refund Policy:** Requests for refunds must be made in writing. There will be a $125 processing fee for cancellations until **September 29, 2017**. After September 29, no refunds can be given.

**Financial Support for Attendance:** The AACR is pleased to provide financial assistance to eligible investigators for participation in this conference, subject to availability of funding. Additional information including award application instructions are available on the Financial Support for Attendance webpage for this conference.

### Method of Payment

- Check or money order enclosed, payable to American Association for Cancer Research, drawn on a U.S. bank.
- VISA □ MasterCard □ American Express

<table>
<thead>
<tr>
<th>Card #</th>
<th>Expiration Date</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Print Name of Cardholder**

**Signature of Cardholder**

Registration fees are payable in U.S. dollars only. Personal checks are acceptable if payable through a U.S. bank.

**Return to:**

**2017 Molecular Targets**

Compusystems
2651 Warrenville Road
Suite 400
Downers Grove, IL 60515
708-344-4444 Fax

¹Nonmember pre-/postdoctoral students must have their registrar, dean, or department head certify that they are enrolled at the university and working toward a degree or fellowship in a field related to cancer research.

²Patient advocates registering for this conference must submit a biography or a curriculum vitae and the advocate verification form to the AACR Survivor and Patient Advocacy Department at advocacy@aacr.org for verification.
2017-2018 SCIENTIFIC CONFERENCES

Third CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference
Conference Cochairs: Stanley Riddell, Robert D. Schreiber, Christoph Huber, and Guido Kroemer
September 6-9, 2017 | Mainz/Frankfurt, Germany

Advances in Modeling Cancer in Mice: Technology, Biology, and Beyond
Conference Cochairs: Cory Abate-Shen, Kevin M. Haigis, Katerina A. Politi, and Julien Sage
September 24-27, 2017 | Orlando, FL

Tenth AACR Conference on The Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved
Conference Cochairs: John M. Carethers, Rick A. Knudsen, Christopher I. Li, and Electra D. Paskett
September 25-28, 2017 | Atlanta, GA

Tumor Immunology and Immunotherapy
Conference Cochairs: James P. Allison, Carl H. June, Miriam Merad, and Giorgio Trinchieri
October 1-4, 2017 | Boston, MA

Addressing Critical Questions in Ovarian Cancer Research and Treatment
Conference Cochairs: Robert C. Bast, Jr., Ursula A. Matulonis, and Anil K. Sood
October 1-4, 2017 | Pittsburgh, PA

Advances in Breast Cancer Research
Conference Cochairs: Myles A. Brown, Tak W. Mak, Ramon E. Parsons, and Laura J. van’t Veer
October 7-10, 2017 | Hollywood, CA

AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics
Scientific Committee Cochairs: Antoni Ribas, James L. Gulley, and Charles Swanton
October 26-30, 2017 | Philadelphia, PA

New Horizons in Cancer Research
Conference Cochairs: Nancy E. Davidson, Kornelia Polyak, Chi Van Dang and Hongyang Wang
November 6-9, 2017 | Shanghai, P.R. China

Prostate Cancer: Advances in Basic, Translational, and Clinical Research
Conference Cochairs: Johann S. de Bono, Karen E. Knudsen, Peter S. Nelson, and Mark A. Rubin
December 2-5, 2017 | Orlando, FL

Pediatric Cancer
Conference Cochairs: Peter C. Adamson, Nada Jabado, and Charles W. M. Roberts
December 3-6, 2017 | Atlanta, GA

San Antonio Breast Cancer Symposium
Presented by CTRC-AACR-BCM
Codirectors: Carlos L. Arteaga, Virginia G. Kaklamani, and C. Kent Osborne
December 5-9, 2017 | San Antonio, TX

Obesity and Cancer
Conference Cochairs: Lewis C. Cantley, Michael N. Pollak, and Elizabeth A. Platz
January 27-30, 2018 | Austin, TX

Immunobiology of Primary and Metastatic CNS Cancer: Multidisciplinary Science to Advance Cancer Immunotherapy
Conference Cochairs: Hideho Okada, Robyn S. Klein, Ignacio Melero, and Patricia S. Steeg
February 12-15, 2018 | San Diego, CA

Targeting DNA Methylation and Chromatin for Cancer Therapy
Conference Cochairs: Stephen B. Baylin, Margaret A. Goodell, and Peter A. Jones
March 1-4, 2018 | Atlanta, GA

AACR Annual Meeting 2018
Program Committee Chair: Elaine R. Mardis
April 14-18, 2018 | Chicago, IL

CALL FOR ABSTRACTS | Abstract Submission Deadline: July 23, 2017
October 26-30, 2017
Pennsylvania Convention Center • Philadelphia, PA

Abstract Submission Deadline: Sunday, July 23
Late-Breaking Abstract Submission Deadline: Thursday, September 7
Early Registration Deadline: Tuesday, August 22

www.AACR.org